Synthesis and structure-activity relationships of the (alkylamino)piperidine-containing BHAP class of non-nucleoside reverse transcriptase inhibitors: Effect of 3-alkylpyridine ring substitution

Journal of Medicinal Chemistry

Volumn 42, Issue 20, 1999, Pages 4140-4149

  Genin, Michael J ^a   Poel, Toni J ^a   Paul D, May ^a   Kopta, Laurice A ^a   Yagi, Yoshihiko ^a   Olmsted, Robert A ^a   Friis, Janice M ^a   Voorman, Richard L ^a   Adams, Wade J ^a   Thomas, Richard C ^a   Romero, Donna L ^a  

^a Discovery Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; ATEVIRDINE; DELAVIRDINE; MUTANT PROTEIN; N [2 [4 [N METHYL N [3 (2 METHYLPROPYL) 2 PYRIDYL]AMINO] 1 PIPERIDINYLCARBONYL] 5 INDOLYL]METHANESULFONAMIDE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PNU 87201; RECOMBINANT PROTEIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CELLS, CULTURED; INJECTIONS, INTRAVENOUS; MALE; MICROSOMES, LIVER; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0033533870     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990051a     Document Type: Article

References (20)

1. Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Res. 1996, 2, 225-246.
2. Romero, D. L. Recent Advances in the Development of HIV Reverse Transcriptase Inhibitors. Annu. Rep. Med. Chem. 1994, 29, 123-132.
3. Richman, D. D. Antiretroviral Drug Resistance: Mechanisms, Pathogenesis, Clinical Significance. Adv. Exp. Med. Biol. 1996, 394, 383-395.
4. Collier, A. C. Efficacy of Combination Antiretroviral Therapy. Adv. Exp. Med. Biol. 1996, 394, 383-395.
5. Vella, S.; France Pirillo, M. Combination Therapy in the Management of HIV Infection. Methods Find. Exp. Clin. Pharm. 1996, 18 (Suppl. C), 23-26.
6. (a) Romero, D. L. Delavirdine Mesylate. Drugs Future 1994, 19 (1), 9-12.
7. (b) Aristoff, P. A. BHAPs. DN&P 1995, 8 (3), 151-155.
8. Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C.-K.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A. S.; Faanes, R.; Eckner, R. J.; Koup, R. A.; Sullivan, J. L. Inhibition of HIV-1 Replication by a Non-Nucleoside Reverse Transcriptase Inhibitor. Science 1990, 250, 1411-1413.
9. Hargrave, K. D.; Proudfoot, J. R.; Grozinger, K. G.; Kapadia, S. R.; Patel, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J.; Behnke, M. L.; Klunder, J. M.; Pal, K.; Skiles, J. W.; McNeil, D. W.; Rose, J. M.; Chow, G. C.; Skoog, M. T.; Wu, J. C.; Schmidt, G.; Engel, W.; Eberlein, W. G.; Saboe, T. D.; Campbell, S. J.; Rosenthal, A. S.; Adams, J. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo-and Dipyridodiazepinones. J. Med. Chem. 1981, 34, 2231-2241.
10. (a) Graul, A.; Rabasseda, X.; Castaner, J. Efavirenz. Drugs Future 1998, 23 (2), 133-141.
11. (b) Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S.; Pettibone, D. J.; O'Brien, J. A.; Ball, R. G.; Balani, S. K.; Lin, J. H.; Chen, I-W.; Schleif, W. A.; Sardana, V. V.; Long, W. J.; Byrnes, V. W.; Emini, E. A. L-743,726 (DMP-266): a Novel, Highly Potent Nonnucleoside Inhibitor of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 1995, 39 (12), 2602-2605.
12. (a) de Clercq, E. How to overcome resistance of HIV-1 to HIV-1 specific reverse transcriptase inhibitors. AIDS 1994, 8 (7), 1020-1021.
13. (b) de Clercq, E. Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) for the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections: Strategies to Overcome Drug Resistance Development. Med. Res. Rev. 1996, 16, 125.
14. Dueweke, T. J.; Pushkarskaya, T.; Poppe, S. M.; Swaney, S. M.; Zhao, J. Q.; Chen, I. S. Y.; Stevenson, M.; Tarpley, W. G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine resistant human immundeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4813-4717.
15. Romero, D. L.; Olmsted, R. A.; Poel, T. J.; Morge, R. A.; Biles, C.; Keiser, B. J.; Kopta, L. A.; Friis, J. M.; Hosley, J. D.; Stefanski, K. J.; Wishka, D. G.; Evans, D. B.; Morris, J., Stehle, R. G.; Sharma, S. K.; Yagi, Y.; Voorman, R. L.; Adams, W. J.; Tarpley, W. G.; Thomas, R. C. Targeting Delavirdine/Atevirdine Resistant HIV-1: Identification of (Alkylamino)piperidine-Containing Bis(heteroaryl)piperazines as Broad Spectrum HIV-1 Reverse Transcriptase Inhibitors. J. Med. Chem. 1996, 39, 3769-3789.
16. Wishka, D. G.; Graber, D. R.; Kopta, L. A.; Olmsted, R. A.; Friis, J. M.; Hosley, J. D.; Adams, W. J.; Seest, E. P.; Castle, T. M.; Dolak, L. A.; Keiser, B. J.; Yagi, Y.; Azhwarsamy, J.; Schlachter, S. T.; Murphy M. J.; Cleek, G. J.; Nugent, R. A.; Poppe, S. M.; Swaney, S. M.; Han, F.; Watt, W.; White, W. L.; Poel, T.-J.; Thomas, R. C.; Voorman, R. L.; Stefanski, K. J.; Stehle, R. G.; Tarpley, W. G.; Morris, J. (-)-6-Chloro-2-[(1-furo[2,3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a New Broad Spectrum HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor. J. Med. Chem. 1998, 41, 1357-1360.
17. Nugent, R. A.; Schlachter, S. T.; Murphy, M. J.; Cleek, G. J.; Poel, T. J.; Wishka, D. G.; Graber, D. R.; Yagi, Y.; Keiser, B. J.; Olmsted, R. A.; Kopta, L. A.; Swaney, S. M.; Poppe, S. M.; Morris, J.; Tarpley, W. G.; Thomas, R. C. Pyrimidine Thioethers: A Novel Class of HIV-1 Reverse Transcriptase Inhibitors with Activity Against BHAP Resistant HIV. J. Med. Chem. 1998, 41, 3793-3803.
18. Genin, M. J.; Poel, T. J.; Yagi, Y.; Biles, C.; Althaus, I.; Keiser, B. J.; Kopta, L. A.; Friis, J. M.; Reusser, F.; Adams, W. J.; Olmsted, R. A.; Voorman, R. L.; Thomas, R. C.; Romero, D. L. Synthesis and Bioactivity of Novel Bis(heteroaryl)piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogues. J. Med. Chem. 1996, 39, 5267-5275.
19. Melnyk, P.; Gasche, J.; Thai, C. Improved syntheses of 2-bromonicotinaldehyde and acid. Synth. Commun. 1993, 23 (19), 2727-2730.
20. Metabolites of the alkylpyridine-substituted AAP-BHAPs tend to be hydroxylated in the side chain or on the pyridine ring. There was also some N-dealkylation of the 4-(alkylamino)-piperidine nitrogen. In general, compounds with these modifications have not shown good inhibition of HIV RT.